137 related articles for article (PubMed ID: 38346605)
1. Recent trends and advances in novel formulations as an armament in Bcl-2/Bax targeted breast cancer.
Samia S; Sandeep Chary P; Khan O; Kumar Mehra N
Int J Pharm; 2024 Mar; 653():123889. PubMed ID: 38346605
[TBL] [Abstract][Full Text] [Related]
2. Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer.
Alam M; Alam S; Shamsi A; Adnan M; Elasbali AM; Al-Soud WA; Alreshidi M; Hawsawi YM; Tippana A; Pasupuleti VR; Hassan MI
Front Oncol; 2022; 12():869672. PubMed ID: 35402265
[TBL] [Abstract][Full Text] [Related]
3. Emerging ways to treat breast cancer: will promises be met?
Samadi P; Saki S; Dermani FK; Pourjafar M; Saidijam M
Cell Oncol (Dordr); 2018 Dec; 41(6):605-621. PubMed ID: 30259416
[TBL] [Abstract][Full Text] [Related]
4. Lobaplatin induces apoptosis in T24 and 5637 bladder cancer cells by regulating Bcl-2 and Bax expression and inhibiting the PI3K/Akt signaling pathway.
Yu Q; Lan T; Ma Z; Wang Z; Zhang C; Jiang Y; Zhao Z
Transl Androl Urol; 2023 Aug; 12(8):1296-1307. PubMed ID: 37680227
[TBL] [Abstract][Full Text] [Related]
5. Bcl-2 Family Members Bcl-xL and Bax Cooperatively Contribute to Bortezomib Resistance in Mantle Cell Lymphoma.
Luanpitpong S; Janan M; Yosudjai J; Poohadsuan J; Chanvorachote P; Issaragrisil S
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430955
[TBL] [Abstract][Full Text] [Related]
6. Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs.
Diepstraten ST; Young S; La Marca JE; Wang Z; Kluck RM; Strasser A; Kelly GL
Cell Death Differ; 2023 Apr; 30(4):1005-1017. PubMed ID: 36755070
[TBL] [Abstract][Full Text] [Related]
7. Directly targeting BAX for drug discovery: Therapeutic opportunities and challenges.
Zhang Z; Hou L; Liu D; Luan S; Huang M; Zhao L
Acta Pharm Sin B; 2024 Jun; 14(6):2378-2401. PubMed ID: 38828138
[TBL] [Abstract][Full Text] [Related]
8. B-cell lymphoma-2 family proteins in the crosshairs: Small molecule inhibitors and activators for cancer therapy.
Gong Q; Wang H; Zhou M; Zhou L; Wang R; Li Y
Med Res Rev; 2024 Mar; 44(2):707-737. PubMed ID: 37983840
[TBL] [Abstract][Full Text] [Related]
9. Differential Expression of Apoptosis-Associated Genes bax and bcl-2 in Ovarian Cancer.
Marx D; Meden H
Methods Mol Med; 2001; 39():687-91. PubMed ID: 21340831
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors.
Taylor ST; Hickman JA; Dive C
J Natl Cancer Inst; 2000 Jan; 92(1):18-23. PubMed ID: 10620629
[TBL] [Abstract][Full Text] [Related]
11. Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer.
Ngoi NYL; Choong C; Lee J; Bellot G; Wong ALA; Goh BC; Pervaiz S
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32131385
[TBL] [Abstract][Full Text] [Related]
12. Bax mediates the apoptosis-sensitizing effect of maspin.
Liu J; Yin S; Reddy N; Spencer C; Sheng S
Cancer Res; 2004 Mar; 64(5):1703-11. PubMed ID: 14996730
[TBL] [Abstract][Full Text] [Related]
13. Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer.
Valko Z; Megyesfalvi Z; Schwendenwein A; Lang C; Paku S; Barany N; Ferencz B; Horvath-Rozsas A; Kovacs I; Schlegl E; Pozonec V; Boettiger K; Rezeli M; Marko-Varga G; Renyi-Vamos F; Hoda MA; Klikovits T; Hoetzenecker K; Grusch M; Laszlo V; Dome B; Schelch K
Br J Cancer; 2023 May; 128(10):1850-1861. PubMed ID: 36918717
[TBL] [Abstract][Full Text] [Related]
14. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.
Choudhary GS; Al-Harbi S; Mazumder S; Hill BT; Smith MR; Bodo J; Hsi ED; Almasan A
Cell Death Dis; 2015 Jan; 6(1):e1593. PubMed ID: 25590803
[TBL] [Abstract][Full Text] [Related]
15. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.
Vallet S; Fan F; Malvestiti S; Pecherstorfer M; Sattler M; Schneeweiss A; Schulze-Bergkamen H; Opferman JT; Cardone MH; Jäger D; Podar K
Breast Cancer Res Treat; 2019 Feb; 173(3):585-596. PubMed ID: 30374681
[TBL] [Abstract][Full Text] [Related]
16. The Bcl-xL and Bax-alpha control points: modulation of apoptosis induced by cancer chemotherapy and relation to TPCK-sensitive protease and caspase activation.
Schmitt E; Sané AT; Steyaert A; Cimoli G; Bertrand R
Biochem Cell Biol; 1997; 75(4):301-14. PubMed ID: 9493953
[TBL] [Abstract][Full Text] [Related]
17. Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells.
Levesley J; Steele L; Brüning-Richardson A; Davison A; Zhou J; Ding C; Lawler S; Short SC
Neuro Oncol; 2018 Jan; 20(2):203-214. PubMed ID: 29016820
[TBL] [Abstract][Full Text] [Related]
18. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis.
Bargou RC; Daniel PT; Mapara MY; Bommert K; Wagener C; Kallinich B; Royer HD; Dörken B
Int J Cancer; 1995 Mar; 60(6):854-9. PubMed ID: 7896458
[TBL] [Abstract][Full Text] [Related]
19. The significance of expression of autophagy-related gene Beclin, Bcl-2, and Bax in breast cancer tissues.
Yao Q; Chen J; Lv Y; Wang T; Zhang J; Fan J; Wang L
Tumour Biol; 2011 Dec; 32(6):1163-71. PubMed ID: 21861179
[TBL] [Abstract][Full Text] [Related]
20. A novel Bcl-2 inhibitor, BM-1197, induces apoptosis in malignant lymphoma cells through the endogenous apoptotic pathway.
Sun YL; Jiang WQ; Luo QY; Yang DJ; Cai YC; Huang HQ; Sun J
BMC Cancer; 2019 Dec; 20(1):1. PubMed ID: 31892356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
